Kyverna Therapeutics, Inc. Investing Cash Flow
Kyverna Therapeutics, Inc. (KYTX) reported Investing Cash Flow of -$14.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- Kyverna Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $36.13M, a 23.87% increase year-over-year.
- Kyverna Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$50.20M, a 999.98% decline year-over-year.
- Kyverna Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$17.29M, a 159.16% decline year-over-year.
- Kyverna Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $22.56M, a 3236.83% increase year-over-year.
- Kyverna Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $40.02M.
- Kyverna Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$160.90M.
- Kyverna Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$8.79M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $36.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$14.07M 10-Q · filed 2026-08-11 | -$31.36M derived: sum of 3 quarters · filed 2026-08-11 | -$8.80M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$50.20M 10-Q · filed 2026-05-12 | -$67.49M derived: sum of 2 quarters · filed 2026-05-12 | -$44.93M derived: sum of 3 quarters · filed 2026-05-12 | -$15.76M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$17.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $5.27M derived: sum of 2 quarters · filed 2026-03-26 | $34.44M derived: sum of 3 quarters · filed 2026-08-11 | $40.02M 10-K · filed 2026-03-26 |
| 2025-09-30 | $22.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $51.72M derived: sum of 2 quarters · filed 2026-08-11 | $57.30M 10-Q · filed 2025-11-12 | $86.52M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $29.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $34.74M 10-Q · filed 2026-08-11 | $63.97M derived: sum of 3 quarters · filed 2026-08-11 | $64.64M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $5.58M 10-Q · filed 2026-05-12 | $34.80M derived: sum of 2 quarters · filed 2026-05-12 | $35.48M derived: sum of 3 quarters · filed 2026-05-12 | -$32.45M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $29.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $29.90M derived: sum of 2 quarters · filed 2026-03-26 | -$38.02M derived: sum of 3 quarters · filed 2026-03-26 | -$160.90M 10-K · filed 2026-03-26 |
| 2024-09-30 | $676.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$67.25M derived: sum of 2 quarters · filed 2025-11-12 | -$190.12M 10-Q · filed 2025-11-12 | -$158.44M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$67.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$190.80M 10-Q · filed 2025-08-12 | -$159.12M derived: sum of 3 quarters · filed 2025-08-12 | -$213.24M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$122.88M 10-Q · filed 2025-05-13 | -$91.20M derived: sum of 2 quarters · filed 2025-05-13 | -$145.32M derived: sum of 3 quarters · filed 2025-05-13 | -$145.32M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $31.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$22.44M derived: sum of 2 quarters · filed 2025-03-27 | -$22.44M derived: sum of 3 quarters · filed 2025-03-27 | -$8.79M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$54.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$54.12M derived: sum of 2 quarters · filed 2024-11-13 | -$40.47M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $13.65M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $13.65M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |